Yang Xiaoyu, Zhang Jidong, Chen Jitang, Xie Yunxuan, Hu Tianci, Luo Qin, Peng Tianhao, Luo Han, Shi Linlin, Wan Jiangling, Wang Jianxin, Yang Xiangliang, Sheng Jianyong
National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, 430074 Wuhan, P. R. China.
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, P. R. China.
Biomater Sci. 2025 Jan 28;13(3):743-757. doi: 10.1039/d4bm01210k.
Oral protein drugs' delivery faces challenges due to multiple absorption barriers for macromolecules. Co-administration with permeation enhancers and encapsulation in nano-carriers are two promising strategies to enhance their oral absorption. Herein, the poly(lactic--glycolic acid) nanoparticles (PLGA NPs) are decorated with polyethylene glycol (PEG) and a traditional Chinese medicine-derived permeation enhancer borneol (BO) for oral insulin delivery. Compared with a physical mixture of BO and PEG-decorated PLGA NPs, PLGA-PEG-BO NPs significantly facilitate insulin permeation across intestinal epithelia through various transcytosis pathways. The relationship among the BO surface density, physico-chemical properties and multiple barriers penetration ability is further investigated. Increasing the BO density boosts penetration through the epithelial cell layer but reduces enzyme and mucus barrier penetration. When the surface PEG density is at 90% and BO density is at 10%, the NPs possess the strongest overall ability to overcome both the mucus layer barrier and epithelial cell barrier, as illustrated by the highest permeation efficiency through Caco-2/HT29-MTX cell co-cultural monolayers. In diabetic rodents, PLGA-PEG-BO NPs exhibit high intestinal safety and a substantial hypoglycemic effect, with insulin availability at 6.22 ± 2.30%, double that of orally delivered insulin PLGA-PEG NPs and far superior to a physical mixture with BO. This study reveals the importance of tailored absorption enhancer decoration for oral protein delivery.
由于大分子存在多种吸收屏障,口服蛋白药物的递送面临挑战。与渗透促进剂共同给药以及封装在纳米载体中是增强其口服吸收的两种有前景的策略。在此,聚(乳酸 - 乙醇酸)纳米颗粒(PLGA NPs)用聚乙二醇(PEG)和一种源自中药的渗透促进剂冰片(BO)进行修饰,用于口服胰岛素递送。与BO和PEG修饰的PLGA NPs的物理混合物相比,PLGA - PEG - BO NPs通过各种转胞吞途径显著促进胰岛素穿过肠上皮细胞的渗透。进一步研究了BO表面密度、物理化学性质与多重屏障穿透能力之间的关系。增加BO密度可提高穿过上皮细胞层的渗透率,但会降低对酶和黏液屏障的穿透率。当表面PEG密度为90%且BO密度为10%时,纳米颗粒具有最强的整体克服黏液层屏障和上皮细胞屏障的能力,通过Caco - 2/HT29 - MTX细胞共培养单层的最高渗透效率证明了这一点。在糖尿病啮齿动物中,PLGA - PEG - BO NPs表现出高肠道安全性和显著的降血糖作用,胰岛素利用率为6.22±2.30%,是口服胰岛素PLGA - PEG NPs的两倍,且远优于与BO的物理混合物。这项研究揭示了为口服蛋白递送定制吸收增强剂修饰的重要性。